ASH 2023: Revumenib Shows Promise in KMT2Ar Acute Leukemia
High overall response rate achieved in patients with acute lymphoblastic leukemia, mixed phenotype acute leukemia, and acute myeloid leukemia
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.